ERBB2 and breast carcinoma: Even though the presence of NumtS can mislead the identification of mtDNA mutations and the heteroplasmy evaluation, it has been found that NumtS are present in approximately 2% of tumors, reaching 5% in lung, skin, breast and uterine cancer and even 15% in HER2 subtypes of breast cancer and in squamous cell lung cancer [14].